2月11日，易思维（杭州）科技股份有限公司登陆上交所科创板。至此，科创板上市公司总数达到 604家。 分行业看，集成电路、生物医药行业景气度明显回升。其中，集成电路产业受人工智能等新兴应用 需求拉动，延续较高景气度。87家公司披露业绩情况显示，合计净利润同比增加约99.49亿元，57家公 司业绩预增或扭亏为盈。 创新药行业则凭借商务拓展交易活跃、出海提速，商业化进程显著加快，招采回暖推动制药类公司 业绩回升。数据显示，26家创新药公司合计实现净利润增加14.49亿元，已披露营业收入的18家公司合 计实现营收241.57亿元，同比增长34.9%。 作为中国"硬科技"企业聚集地，科创板的板块产业图谱与现代化产业体系建设同向而行，尤其是在 新一代信息技术、生物医药、高端装备制造等战略性新兴产业领域，已形成"链主引领、上下协同"的发 展格局。 与此同时，板块业绩成长韧性凸显。截至2月9日，科创板已有391家公司以业绩预告或快报形式披 露2025年度预计业绩，其中近六成净利润实现同比增长。 "科创板上市公司已超过600家，这不仅是一个数量里程碑，它标志着这块'试验田'已茁壮成长为中 国硬科技创新的战略基座与资本市场改革 ...

2025年，沪市公司经营韧性与结构亮点进一步显现，在"质"与"量"的双重维度上，助力中国经济破浪前 行。数据显示，截至2月9日，271家沪市主板公司发布2025年业绩预告，其中168家预增、85家预计扭 亏。391家科创板公司以业绩预告或快报形式披露了2025年业绩情况，近六成公司预计净利润实现同比 增长，其中39家预计净利润同比倍增、51家预计扭亏为盈。 一幅稳增长、优结构的沪市公司全年发展图景徐徐展开。记者关注到，业绩突出的公司主要集中在有色 金属、电子等行业。有色金属受产品价格与产销量共同驱动，电子行业在AI需求带动下维持较快增 长。与此同时，一批龙头公司预计盈利规模仍处于高位，持续发挥沪市主板"压舱石"作用。 有色金属行业发展尽显韧性 2025年，在全球地缘政治摩擦多发和主要经济体降息预期的推动下，黄金的避险与货币属性愈加显现， 黄金价格屡创新高，直接增厚了拥有巨量黄金储备企业的利润。 有色行业规模以上企业工业增加值增长6.9%，高于全国规上工业增加值增速1.0个百分点，十种有色金 属产量首次突破8000万吨大关。规模以上企业实现利润总额5284.5亿元，同比增长25.6%，创下历史新 高。下游新兴产 ...

行业板块情况 板块整体调整：2026年1月以来，医药生物板块主题轮动加快，创新药领域阶段性获利了结压力显现。 技术性回调：股价在1月受收购传闻推动冲高至94.90美元，近期回调属正常波动。业绩面压力：公司 2025年第三季度财报显示营收为0，净亏损6580万美元，研发投入持续，短期盈利压力或影响市场信 心。竞争担忧：CEO提及对GLP-1仿制药冲击的担忧，可能引发市场对行业竞争加剧的疑虑。 机构观点 经济观察网硕迪生物近期股价波动与基本面利好形成反差，主要受市场情绪、板块调整及技术面因素影 响。 近期事件 根据公开信息，硕迪生物于2025年12月30日与罗氏及基因泰克达成非独家专利许可协议，获得1亿美元 预付款，并有权收取基因泰克口服GLP-1药物CT-996未来销售额的低个位数百分比特许权使用费。该合 作未限制公司核心管线的研发权，且提供了非稀释性资金支持。 股票近期走势 尽管存在上述利好，硕迪生物股价在近期呈现下跌趋势：区间跌幅14.41%，振幅达22.57%，最低触及 72.10美元。最新交易日收盘价75.70美元，单日下跌3.63%，同期生物技术板块下跌0.45%。下跌期间成 交活跃，显示资金分歧较大 ...

Core Viewpoint - The significant drop in the scale of bank wealth management products in January indicates a major shift in the industry, reflecting a healthy correction of inflated growth driven by unsustainable business models [1][4][26]. Group 1: Industry Scale Changes - In January, the scale of 14 leading bank wealth management subsidiaries decreased by over 800 billion, accounting for approximately 75% of the total wealth management industry scale, which was over 33 trillion at the end of 2025 [1][25]. - The total industry scale is estimated to have dropped by over 1 trillion in January, marking a substantial decline compared to previous years where the scale remained relatively stable [3][25]. Group 2: Business Model Implications - The decline in scale is seen as a necessary adjustment, as the previous growth was largely fueled by "retained earnings" and "ranking models," which artificially inflated yield levels [4][27]. - The end of the "ranking model" signifies a downward adjustment in the yield of pure debt wealth management products, which will lower the actual risk-free rate for Chinese residents and potentially increase the valuation of all risk assets [5][28]. Group 3: Future Industry Dynamics - The shift away from old business models necessitates a focus on research capabilities, product line structuring, and channel service improvements, leading to a transformation in wealth management product structures [5][28]. - The rise of multi-asset wealth management products indicates a growing trend towards diversification and a need for wealth management firms to adapt to changing market conditions [5][28]. Group 4: Market Environment - The low interest rate environment is pushing the industry towards a multi-asset investment approach, emphasizing the importance of asset allocation for both investment advisors and individual investors [5][29]. - The current market dynamics suggest that firms lacking the ability to provide effective asset allocation will struggle to remain competitive in the evolving landscape [5][29].

Core Insights - The report emphasizes the focus on undervalued and performance-recovering sectors within the medical services and consumer segments, predicting a fundamental improvement in 2026 [4]. Group 1: Investment Strategy - The report maintains an "outperform" rating for the sector, indicating a positive outlook for the medical and consumer-related segments [2]. - Key areas of focus include medical services, pharmacies, and home medical devices, which are expected to see performance recovery and valuation improvements in 2026 [4]. Group 2: Sector Analysis - Medical services are anticipated to recover due to improved supply structure and consumer environment, with leading companies expected to show positive earnings guidance for 2026 [4]. - The pharmacy sector has shown significant marginal improvement since Q3 2025, with leading companies experiencing quarterly performance enhancements [4]. - Home medical devices are expected to benefit from increased product penetration and domestic production rates, contributing to sustained performance growth [4]. Group 3: Notable Companies - The report highlights specific companies to watch, including Aier Eye Hospital, Yuyue Medical, and Yifeng Pharmacy, which are positioned for growth in their respective segments [4]. - The investment portfolio for February 2026 includes a mix of A-share and H-share companies, such as Mindray Medical, WuXi AppTec, and Kangfang Biotech, indicating a diversified approach to investment [4]. Group 4: Market Performance - The medical sector outperformed the broader market in January 2026, with a 3.14% increase compared to the 1.49% rise of the CSI 300 index [10]. - Sub-sectors such as medical services and medical devices showed significant gains, with respective increases of 8.82% and 5.28% [17]. Group 5: Macro Data - In 2025, the pharmaceutical manufacturing industry reported a total revenue of 24,870 billion yuan, reflecting a slight decline of 1.2% year-on-year, while total profits increased by 2.7% [9]. - The retail sales of pharmaceuticals reached 7,294 billion yuan, with a year-on-year growth of 1.8%, indicating a stable demand in the market [9].

Core Viewpoint - The significant drop in the scale of bank wealth management products in January indicates a major shift in the industry, suggesting that the previous growth was unsustainable and that a transformation in business models is necessary [1][6]. Group 1: Industry Scale Changes - In January, the scale of 14 leading bank wealth management subsidiaries decreased by over 800 billion, which represents approximately 75% of the total wealth management industry scale, indicating a total industry drop of over 1 trillion [1][3]. - The scale drop of 1 trillion is substantial, especially when compared to a decrease of over 1200 billion in January 2024 and an increase of about 500 billion in January 2025, highlighting a significant shift in investor behavior [3]. Group 2: Business Model Transformation - The release of retained earnings and the end of the "ranking" business model for wealth management companies signal a need for a focus on research capabilities, product line layout, and channel service capabilities [4][7]. - The competition landscape in the wealth management industry is expected to undergo drastic changes, with a shift away from unsustainable business practices towards more robust investment strategies [5][7]. Group 3: Market Implications - The decline in wealth management scale reflects a healthy adjustment in the industry, as it removes inflated growth driven by unsustainable practices [6]. - The end of the previous business model will lead to a decrease in pure debt wealth management yields, which will lower the actual risk-free rate for Chinese residents, potentially increasing the valuation of risk assets [7]. - The transition in wealth management is not just a change for wealth management subsidiaries but requires a comprehensive transformation across management and sales channels [7]. Group 4: Investment Strategy Recommendations - The current low-interest-rate environment necessitates a multi-asset investment approach, emphasizing the importance of asset allocation for both investment advisors and individual investors [7][8]. - The rise of multi-asset wealth management products indicates a shift in investor preferences, with a significant increase in the allocation towards fixed income and public funds [7].

Core Insights - The recent refinancing regulations introduced by the Shanghai, Shenzhen, and Beijing stock exchanges aim to facilitate financing for high-quality listed companies, particularly in the tech sector, by improving review speed, flexibility in fund usage, and tolerance for R&D investments [1] - The effectiveness of these policies is contingent upon the actual participation of institutional investors, rather than merely following market trends or concepts [1] Group 1: Institutional Participation - Investors should prioritize examining the "institutional inventory" data to gauge the active participation of institutional funds in trading, rather than being swayed by market concepts [3][5] - A case study revealed that a stock associated with the innovative drug concept had been actively monitored by institutions for over six months, despite its recent volatility, indicating that institutional interest was present before the market hype [3][5] - The "institutional inventory" data serves as a critical indicator of whether institutions are genuinely involved in a stock, which can significantly influence its price movement [5][9] Group 2: Market Dynamics - Stocks that appear stagnant may still have underlying institutional activity, which can lead to sudden price increases when the market eventually recognizes this participation [7][9] - A stock in the liquor sector failed to appreciate in value due to a lack of institutional involvement, despite positive fundamental indicators, highlighting the importance of institutional sentiment in price movements [11] - The overall market behavior is driven by the actions of institutional investors, who possess the financial power to dictate stock trends [11] Group 3: Investment Strategy - Investors are encouraged to adopt a data-driven approach, focusing on objective metrics such as institutional participation rather than emotional reactions to market fluctuations [12] - The formula for sustainable investment capability emphasizes the importance of objective market recognition and structured decision-making processes, minimizing emotional interference [12] - Upgrading investment knowledge involves shifting from subjective speculation to relying on objective data regarding institutional actions, which is essential for long-term success in the market [12]

Core Viewpoint - The company Xinnoway (300765.SZ) is currently facing significant stock price volatility due to poor performance forecasts and market sentiment, with a recent stock price of 35.79 yuan reflecting a 2.40% increase on the day but a 12.66% decline over the past 20 days [1]. Group 1: Stock Performance - As of February 10, 2026, Xinnoway's stock price was reported at 35.79 yuan, with a daily increase of 2.40% [1]. - The stock has experienced a cumulative decline of 3.82% over the past 5 days and 12.66% over the past 20 days [1]. - The current price-to-earnings ratio (TTM) is negative at -458.45, indicating the company is in a loss position [1]. Group 2: Institutional Insights - Southwest Securities reported on February 8, 2026, that the A-share innovative drug sector declined by 1.32%, with Xinnoway's weekly drop reaching 12.53%, placing it among the worst performers in the sector [1]. - The overall institutional rating is neutral, with profit forecasts indicating a net profit of 54 million yuan for 2025 (a 0.51% year-on-year increase) and an expected improvement to 73 million yuan in 2026 (a 35.19% year-on-year increase) [1]. - The uncertainty surrounding the innovative drug development process remains a significant risk factor [1]. Group 3: Recent Events - On January 30, 2026, Xinnoway completed a management adjustment, promoting the former board secretary Dai Long (a post-90s executive) to general manager, with Xu Wen taking over as board secretary [2]. - On the same day, the company announced a strategic cooperation with AstraZeneca, involving an upfront payment of 1.2 billion USD, with Giant Bio receiving 35% [2]. - The market reacted cautiously to the appointment of a young executive and the performance decline, resulting in a stock price drop of 15.72% on that day [2].

Core Viewpoint - The upcoming Chinese New Year holiday will lead to a 10-day market closure for A-shares, while Hong Kong stocks (H-shares) will continue trading, raising questions about whether H-shares can perform independently during this period. The recent adjustments in H-shares, combined with the surge in AI applications, prompt an analysis of whether the market has reached a correction point [1][3]. Market Trends - Historically, the Hang Seng Index has shown an 82% probability of rising in the three trading days before the Spring Festival, with a 40%-60% chance of increasing after the holiday. The correlation between H-shares and A-shares has strengthened, while the correlation with U.S. stocks has weakened, suggesting a potential for passive upward movement in H-shares [3]. Sector Performance - The Hang Seng Technology Index has seen significant performance metrics, with an average increase of 72.7% from Christmas to the Spring Festival. The average increase for the Hang Seng Index during the same period is 3.8% [4]. Investment Opportunities - The recent pullback in H-shares has made valuations more attractive, with expectations of a rebound. The Hang Seng Technology Index's price-to-earnings (P/E) ratio is currently at 24.5, which is below the historical average, indicating a favorable entry point for investors [7][8]. Innovation and Drug Development - Significant partnerships in the biotech sector, such as the collaboration between Innovent Biologics and Eli Lilly, highlight the potential for innovation in the pharmaceutical industry. This partnership includes a $350 million upfront payment and potential milestone payments totaling up to $8.5 billion [9]. Consumer Sector Dynamics - As the Spring Festival approaches, consumer activity is expected to rise, particularly in sectors like gold retail and hospitality. Government policies aimed at boosting consumption are likely to enhance market sentiment and drive growth in the consumer sector [11]. Dividend Strategies - In a low-interest-rate environment, dividend strategies are becoming increasingly attractive. The dividend yield for H-shares remains higher compared to A-shares, making them a compelling option for investors seeking stable returns [12][13]. Automotive Sector Growth - The automotive sector is poised for growth due to supportive policies and technological advancements in smart driving. The introduction of new policies for electric vehicle purchases is expected to stimulate demand, while advancements in autonomous driving technology present further opportunities [14][15].

Core Viewpoint - The peak of overseas liquidity shock has passed, and the earnings expectations for the Hong Kong tech sector have been continuously adjusted downwards since September, but have recently stabilized, indicating that current stock prices reflect a phase of market adjustment [1] Group 1: Market Conditions - The relative valuation of the Hong Kong tech sector has reached historical lows, with a regulatory and development environment significantly better than in previous years, indicating that the sector is significantly undervalued [1] - The industry is progressing smoothly, with various large models being promoted actively by companies like Tencent and Alibaba during the Spring Festival, continuously catalyzing the AI industry [1] Group 2: Investment Opportunities - The Hong Kong Tech ETF (513020) tracks the Hong Kong Stock Connect Technology Index (931573), covering core assets in sectors such as internet, innovative pharmaceuticals, and new energy vehicles, reflecting the diversified characteristics of the tech industry and the overall performance of core tech companies in the Hong Kong market [1] - The Hong Kong Stock Connect Technology Index has outperformed the Hang Seng Tech Index by over 140% since its base date at the end of 2014, with a cumulative return of 224.25% compared to the Hang Seng Tech Index's 83.87%, indicating long-term outperformance against similar indices [1]